In the most recent after-hours trading, Natera, Inc. (NTRA) caught the eye of investors, with its stock price climbing to $69.95. This surge represents a robust increase of $5.20 per share, equivalent to an 11.191% hike, a clear indicator of the market’s burgeoning trust in the company.
A lively exchange was reflected in the trading volume of 120,400 shares, underscoring the vibrant interest in Natera’s trajectory. This substantial activity in after-hours trading speaks volumes about the market’s optimistic outlook on Natera’s future endeavors.
Most Recent Highlights
Just recently, on January 16, 2024, Natera stood in the legal spotlight as they navigated through a patent infringement case in the federal court of Texas’ western district, brought forth by Ravgen, Inc. The verdict favored Ravgen with a $57 million compensation, a sum far less than their $410 million claim.
Notably, the jury decided Natera’s infringement wasn’t deliberate. Natera reassured everyone that this legal issue would not disrupt its service commitment, especially considering the patent at hand has reached its expiry. Unconvinced by the jury’s decision, Natera is preparing for an appeal.
Earlier, on January 9, 2024, Natera shared uplifting preliminary financial results for the fourth quarter and the whole of 2023, up until December 31. The company is celebrating a 38% year-over-year increase for the quarter, with revenues of around $300 million, and an overall annual jump of 30%, culminating in revenues of approximately $1.07 billion.
These encouraging figures are part of a presentation discussed at the prestigious 42nd Annual J.P. Morgan Healthcare Conference and can be found in the investor relations section of Natera’s website. A comprehensive financial disclosure for the fourth quarter and the full year is on the docket for February 2024’s earnings call.
